Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001214659-25-004123
Filing Date
2025-03-10
Accepted
2025-03-10 16:30:43
Documents
59
Period of Report
2025-01-31

Document Format Files

Seq Description Document Type Size
1 z3425010q.htm   iXBRL 10-Q 998041
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 7823
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 7608
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 5002
  Complete submission text file 0001214659-25-004123.txt   4520971

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alzm-20250131.xsd EX-101.SCH 41728
6 XBRL CALCULATION FILE alzm-20250131_cal.xml EX-101.CAL 32461
7 XBRL DEFINITION FILE alzm-20250131_def.xml EX-101.DEF 134016
8 XBRL LABEL FILE alzm-20250131_lab.xml EX-101.LAB 337740
9 XBRL PRESENTATION FILE alzm-20250131_pre.xml EX-101.PRE 269961
61 EXTRACTED XBRL INSTANCE DOCUMENT z3425010q_htm.xml XML 574948
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40483 | Film No.: 25724204
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)